Decreased regulatory T-cells and CD4+/CD8+ratio correlate with disease onset and progression in patients with generalized vitiligo-Reference-Cited by-同舟云学术

Decreased regulatory T-cells and CD4+/CD8+ratio correlate with disease onset and progression in patients with generalized vitiligo

Published:2013-05-13 Issue:4 Volume:26 Page:586-591
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res

Author:

Dwivedi Mitesh¹,Laddha Naresh C.¹,Arora Prateek¹,Marfatia Yogesh S.²,Begum Rasheedunnisa¹

Affiliation:

1. Department of Biochemistry, Faculty of Science; The Maharaja Sayajirao University of Baroda; Vadodara; India

2. Department of Skin and VD; Sir Sayajirao Gaikwad Medical College, The Maharaja Sayajirao University of Baroda; Vadodara; India

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcmr.12105/fullpdf

Reference31 articles.

1. Evaluation of circulating CD4 + CD25high FoxP3 + T lymphocytes in active non-segmental vitiligo;Abdallah;J. Pan-Arab League Dermatol.,2009

2. CD4 + CD25(hi) regulatory T cells in healthy males and females mediate gender difference in the prevalence of autoimmune diseases;Afshan;Clin. Lab.,2012

3. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families;Alkhateeb;Pigment Cell Res.,2003

4. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo;Ben Ahmed;Pigment Cell Melanoma Res.,2011

5. Association of generalized vitiligo with HLA class II loci in patients from the Indian subcontinent;Birlea;J. Invest. Dermatol.,2013

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vitiligo: advances in pathophysiology research and treatment development;Trends in Molecular Medicine;2024-09

2. Role of serum cd4+, cd25+, and foxp3+ cells’ segmental and nonsegmental vitiligo;Egyptian Journal of Dermatology and Venereology;2024-09

3. Up-and-Coming Drugs for the Treatment of Vitiligo;ANN DERMATOL;2024

4. Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo;Archives of Dermatological Research;2024-07-18

5. Exosome-derived microRNAs: emerging players in vitiligo;Frontiers in Immunology;2024-07-08